Liangyu Bie

765 total citations
29 papers, 567 citations indexed

About

Liangyu Bie is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Molecular Biology. According to data from OpenAlex, Liangyu Bie has authored 29 papers receiving a total of 567 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Surgery and 11 papers in Molecular Biology. Recurrent topics in Liangyu Bie's work include Gastric Cancer Management and Outcomes (9 papers), Esophageal Cancer Research and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Liangyu Bie is often cited by papers focused on Gastric Cancer Management and Outcomes (9 papers), Esophageal Cancer Research and Treatment (6 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Liangyu Bie collaborates with scholars based in China, Norway and Netherlands. Liangyu Bie's co-authors include Beibei Chen, Xiaobing Chen, Wenying Deng, Antonius G.J.M. Hanselaar, Peter C.M. de Wilde, Jeroen van der Laak, Saiqi Wang, Suxia Luo, Huifang Lv and Xiaokun Shen and has published in prestigious journals such as Journal of Clinical Oncology, Scientific Reports and Annals of Oncology.

In The Last Decade

Liangyu Bie

27 papers receiving 558 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liangyu Bie China 14 283 219 163 124 66 29 567
WEN-SHIN CHANG Taiwan 12 250 0.9× 158 0.7× 125 0.8× 57 0.5× 53 0.8× 74 527
Zhiqing Fang China 14 285 1.0× 213 1.0× 124 0.8× 158 1.3× 42 0.6× 30 587
Helin Feng China 15 238 0.8× 197 0.9× 130 0.8× 144 1.2× 44 0.7× 47 557
Mengting Li China 11 294 1.0× 214 1.0× 96 0.6× 270 2.2× 61 0.9× 35 559
Katsuki Miyazaki Japan 12 126 0.4× 100 0.5× 125 0.8× 73 0.6× 59 0.9× 35 414
Chunhua Ling China 17 422 1.5× 296 1.4× 111 0.7× 112 0.9× 53 0.8× 45 658
Fengyun Hao China 12 262 0.9× 167 0.8× 76 0.5× 87 0.7× 41 0.6× 22 399
Hao Zhou China 15 464 1.6× 313 1.4× 113 0.7× 206 1.7× 54 0.8× 60 770
Gabriel Olmedilla Spain 12 237 0.8× 132 0.6× 125 0.8× 239 1.9× 53 0.8× 17 556

Countries citing papers authored by Liangyu Bie

Since Specialization
Citations

This map shows the geographic impact of Liangyu Bie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liangyu Bie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liangyu Bie more than expected).

Fields of papers citing papers by Liangyu Bie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liangyu Bie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liangyu Bie. The network helps show where Liangyu Bie may publish in the future.

Co-authorship network of co-authors of Liangyu Bie

This figure shows the co-authorship network connecting the top 25 collaborators of Liangyu Bie. A scholar is included among the top collaborators of Liangyu Bie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liangyu Bie. Liangyu Bie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bie, Liangyu, Wei Chen, Suxia Luo, et al.. (2025). Benmelstobart plus anlotinib and chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: A phase 2 study. Cell Reports Medicine. 6(6). 102145–102145.
2.
3.
Chen, Wei, Xueting Wang, Xinyi Yang, et al.. (2025). A retrospective multicenter study on the efficacy and safety of disitamab vedotin monotherapy versus combination with anti-PD-1 immunotherapy in advanced gastric cancer. Scientific Reports. 15(1). 2232–2232. 1 indexed citations
4.
5.
Chen, Wei, Mengyu Wang, Wenying Deng, et al.. (2024). Tumor-associated macrophage clusters linked to immunotherapy in a pan-cancer census. npj Precision Oncology. 8(1). 176–176. 8 indexed citations
6.
Yuan, Weiwei, Shanshan Hou, Huahua Li, et al.. (2022). The Antigastric Cancer Effect of Triptolide is Associated With H19/NF-κB/FLIP Axis. Frontiers in Pharmacology. 13. 918588–918588. 15 indexed citations
7.
8.
9.
Wang, Mengyu, Quanli Gao, Shasha Yuan, et al.. (2022). Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors. Cancer Immunology Immunotherapy. 72(1). 23–37. 10 indexed citations
10.
Li, Ning, Zhi Li, Qiang Fu, et al.. (2022). Phase II study of SHR1210 and trastuzumab in combination with CAPOX for neoadjuvant treatment of HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 40(4_suppl). 296–296. 7 indexed citations
11.
Li, Ning, Wenying Deng, Guifang Zhang, et al.. (2021). Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Frontiers in Oncology. 11. 728854–728854. 4 indexed citations
12.
Bie, Liangyu, Dan Li, Wei Yan, et al.. (2020). HOTAIR Competitively Binds MiRNA330 as a Molecular Sponge to Increase the Resistance of Gastric Cancer to Trastuzumab. Current Cancer Drug Targets. 20(9). 700–709. 14 indexed citations
13.
Li, Ningning, Qiang Fu, Wenying Deng, et al.. (2020). 160P Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology. 31. S1302–S1302. 4 indexed citations
14.
15.
Li, Ning, Wei Shen, Wenying Deng, et al.. (2020). Clinical features and the efficacy of adjuvant chemotherapy in resectable small bowel adenocarcinoma: a single-center, long-term analysis. Annals of Translational Medicine. 8(15). 949–949. 6 indexed citations
16.
Lv, Huifang, Caiyun Nie, Beibei Chen, et al.. (2019). MicroRNA-6884-5p Regulates the Proliferation, Invasion, and EMT of Gastric Cancer Cells by Directly Targeting S100A16. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 28(3). 225–236. 27 indexed citations
17.
Wang, Saiqi, et al.. (2018). Steroidal dimer by001 inhibits proliferation and migration of esophageal cancer cells via multiple mechanisms. Cancer Chemotherapy and Pharmacology. 83(1). 179–189. 3 indexed citations
18.
Chen, Xiaobing, Bojian Xie, Feng Zhu, et al.. (2017). Direct binding of microRNA-21 pre-element with Regorafenib: An alternative mechanism for anti-colorectal cancer chemotherapy?. Journal of Molecular Graphics and Modelling. 73. 48–53. 13 indexed citations
19.
Chen, Beibei, Xiaobing Chen, Liangyu Bie, et al.. (2015). Decreased expression of miR-542-3p exerts growth inhibitory functions in esophageal cancer. Journal of Cancer Research and Therapeutics. 11(Suppl 1). S24–S28. 16 indexed citations
20.
Laak, Jeroen van der, et al.. (2002). The effect of Replens(R) on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. Journal of Clinical Pathology. 55(6). 446–451. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by WEN-SHIN CHANG Breakdown of academic impact, for papers by Zhiqing Fang Breakdown of academic impact, for papers by Helin Feng Breakdown of academic impact, for papers by Mengting Li Breakdown of academic impact, for papers by Katsuki Miyazaki Breakdown of academic impact, for papers by Chunhua Ling Breakdown of academic impact, for papers by Fengyun Hao Breakdown of academic impact, for papers by Hao Zhou Breakdown of academic impact, for papers by Gabriel Olmedilla
Rankless by CCL
2026